$0.96
7.69% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Jaguar Health, Inc. Stock price

$0.96
-0.20 17.24% 1M
-14.35 93.73% 6M
-8.12 89.43% YTD
-21.94 95.81% 1Y
-8,279.04 99.99% 3Y
-8,929.29 99.99% 5Y
-96,106,499.04 100.00% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.08 7.69%
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Key metrics

Market capitalization $8.87m
Enterprise Value $31.85m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 3.04
P/S ratio (TTM) P/S ratio 0.85
P/B ratio (TTM) P/B ratio 0.74
Revenue growth (TTM) Revenue growth -2.25%
Revenue (TTM) Revenue $10.48m
EBIT (operating result TTM) EBIT $-29.86m
Cash position $13.27m
EPS (TTM) EPS $-16.10
P/E forward negative
P/S forward 0.76
EV/Sales forward 2.35
Short interest 3.60%
Show more

Is Jaguar Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Jaguar Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Jaguar Health, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Jaguar Health, Inc.:

Buy
100%

Financial data from Jaguar Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
10 10
2% 2%
100%
- Direct Costs 4.44 4.44
22% 22%
42%
6.04 6.04
15% 15%
58%
- Selling and Administrative Expenses 18 18
1% 1%
172%
- Research and Development Expense 15 15
20% 20%
148%
-28 -28
10% 10%
-262%
- Depreciation and Amortization 2.36 2.36
2% 2%
23%
EBIT (Operating Income) EBIT -30 -30
10% 10%
-285%
Net Profit -38 -38
5% 5%
-360%

In millions USD.

Don't miss a Thing! We will send you all news about Jaguar Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jaguar Health, Inc. Stock News

Neutral
Seeking Alpha
about 6 hours ago
Jaguar Health, Inc. (NASDAQ:JAGX ) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President & Chief Executive Officer Pravin Chaturvedi - Chief Scientific Officer Carol Lizak - Chief Financial Officer Operator [Call Starts Abruptly] before I turn the call over to management, I'd like to remind you that management may make forward-looking ...
Neutral
Accesswire
3 days ago
The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million Jaguar reported significant results in breast cancer patients in its phase 3 OnTarget trial for its cancer supportive care drug crofeleme...
Neutral
Accesswire
5 days ago
Click here to register for investor webcast Company plans to file its Earnings Report on November 13, 2024 on Form 10-Q for the quarter ended September 30, 2024 SAN FRANCISCO, CA / ACCESSWIRE / November 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, November 13, 2024 at 8:30 a.m. Eastern to review third-quarter 2024 f...
More Jaguar Health, Inc. News

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Lisa Conte
Employees 49
Founded 2013
Website www.jaguar.health

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today